# Safety and Tolerability of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis

> **NCT01169844** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 28 (actual)

## Conditions studied

- Psoriatic Arthritis

## Interventions

- **BIOLOGICAL:** AIN457A
- **OTHER:** Other

## Key facts

- **NCT ID:** NCT01169844
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2021-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01169844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01169844, "Safety and Tolerability of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01169844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*